Today genetic testing company 23andMe announced a $60 million deal with pharmaceutical giant Genentech to identify new drug targets and therapies, including for Parkinson’s disease (PD).

Genentech is paying for genomic sequencing for 3,000 Parkinson’s patients or first degree relatives in the robust 23andMe Parkinson’s Community. The genome is one’s complete set of DNA and could be the source of new insight into the onset and progression of Parkinson’s.

We’ll share more when the sequencing study is actively recruiting. Read more today from Matt Herper on Forbes.com.